Pharma: Other News To Note
Novartis AG, of Basel, Switzerland, said the FDA approved mTOR inhibitor Zortress (everolimus) for the prophylaxis of organ rejection in adults receiving liver transplants.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.